Novel Hypertension Drug Tonlamarsen Shows Lasting Blood Pressure Effects Post-Treatment

A groundbreaking study published in the Journal of American College of Cardiology and further elaborated at the European Society of Cardiology Congress 2026, reveals that the investigational drug Tonlamarsen leads to sustained reductions in plasma angiotensinogen and, crucially, persistent blood pressure improvements even after patients stop treatment. This marks a potential paradigm shift for millions suffering from uncontrolled hypertension, a condition where current daily medications often fall short in long-term adherence and efficacy. The KARDINAL trial demonstrated that while monthly Tonlamarsen doses significantly lowered plasma angiotensinogen more than a single dose, both regimens showed clinically meaningful reductions in office systolic blood pressure from baseline, with sustained effects after treatment cessation. This development comes as uncontrolled hypertension continues to be a silent killer globally, affecting 1.4 billion people in 2024 and contributing to over 10 million deaths annually from conditions like stroke and heart attack. Current standard treatments, often involving multiple daily pills, struggle with patient adherence and don't always achieve optimal blood pressure control, leaving more than half of hypertensive patients uncontrolled. Tonlamarsen, an antisense oligonucleotide, tackles hypertension at its root by targeting the liver's production of angiotensinogen, a key component of the Renin-Angiotensin-Aldosterone System (RAAS) which regulates blood pressure. This upstream approach differs from many existing drugs that act further down the RAAS pathway. With these promising Phase 2 results, the focus now shifts to further clinical validation and regulatory pathways. Kardigan, the company behind Tonlamarsen, is already planning or has initiated the KARDINAL-ASH Phase 2b clinical trial, specifically targeting patients with acute severe hypertension post-hospitalization, indicating a push towards high-risk populations. If successful, Tonlamarsen long-lasting effect and less frequent dosing could dramatically improve patient compliance and reduce the global burden of cardiovascular disease, offering a much-needed new tool in the fight against high blood pressure.